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bWe are delighted to provide readers of the Journal with this
review of major scientific work published or presented as a
late-breaking trial in 2012. We hope that the paper will
provide a broad overview for general cardiologists, as well as
a framework for more detailed study for those interested in
interventional cardiology.
Structural Heart Disease
A. Transcatheter aortic valve replacement (TAVR). There
ere excellent reviews on pathophysiology of aortic stenosis
AS) (1); quantification of AS severity (2); low-flow low-
radient (LF-LG) AS (3), 10-year outcome of TAVR in
0,000 patients (4,5), a current state of the art (6), and
ultimodality imaging for TAVR (7). Two expert docu-
ents described operator and institutional requirements for
AVR (8,9), and the Valve Academic Research Consor-
ium (VARC-2) developed standardized definitions (10). A
roposed AS classification based on valve area, ventricular
lood flow, and transaortic pressure gradients may allow
etter characterization of AS patients (11). Compared to
atients with severe AS, normal left ventricular (LV) func-
ion, and high gradients, those with LG have 2-fold
reater 5-year mortality (12,13).
Three-dimensional angiographic reconstruction of a ro-
ational aortic root angiogram can predict the ideal deploy-
ent angle, and is highly correlated with computed tomog-
aphy (CT) (14). Operators should anticipate aortic
ovement of the Edwards SAPIEN (ES) and SAPIEN XT
ESXT) (Edwards Lifesciences Irvine, California) valve
uring deployment, to optimize valve position (15). The
ortic annulus is elliptical in diastole and rounded in systole;
ppreciable changes in cross-sectional area but negligible
hanges in perimeter suggest that annulus perimeter is
deally suited for valve sizing (16). ES and ESXT maintain
xcellent circularity, full expansion, and no stent fractures
.5 years after implantation (17).
Transfemoral (TF), transapical (TA), and transaortic
TAo) approaches are used for TAVR. One study demon-
trated the safety of a fully percutaneous transaxillary ap-
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emostasis (18). Percutaneous TF TAVR was performed in
ll but 1 of 137 patients using vascular pre-closure, resulting
n a dramatic decline in vascular complications (19). A
ercutaneous TF approach, local anesthesia, and vascular
losure were used in 151 patients, with conversion to general
nesthesia in 3.3%, procedural success in 95.4%, and 30-day
omposite safety (death, stroke, myocardial infarction [MI],
ajor bleeding, vascular complications, acute kidney injury,
epeat intervention for valve dysfunction) in 15.9% (20).
here is a significant learning curve with the ES during the
rst 30 cases (21).
A meta-analysis of 3,519 patients after ES, ESXT, and
edtronic CoreValve (MCV; Medtronic, Minneapolis,
innesota) reported 30-day composite safety, 30-day mor-
ality, and 1-year mortality in 32.7%, 7.8%, and 22.1%,
espectively (22). Permanent pacemaker implantation (PPI)
as more frequent after MCV (28.9% vs. 4.9%, p  0.001).
he Canadian ES registry reported mortality in 55.5% at 4
ears (noncardiac 59.2%, cardiac 23.0%, and unknown
7.8%) (23). Predictors of late mortality were chronic pulmo-
ary disease, chronic kidney disease, chronic atrial fibrillation
AF), and frailty. In PARTNER (Placement of Aortic Trans-
atheter Valve Trial) trial cohort A, TAVR was associated
ith similar mortality and stroke at 2 years, but more
aravalvular aortic regurgitation (PAR) (24); PAR was
ssociated with late mortality. The FRANCE-2 registry
eported mortality at 30 days and 1 year of 9.7% and 24.0%,
espectively (25). Predictors of mortality included European
ystem for Cardiac Operative Risk Evaluation (Euro-
CORE), New York Heart Association functional class,
A TAVR, and PAR. The Italian CoreValve registry
eported all-cause and cardiac mortality of 34.8% and
3.5%, respectively (26). Pathology of transcatheter valves
xplanted at surgery or autopsy revealed a paucity of valve
egeneration and fibrous ingrowth, but significant myocar-
ial amyloidosis in 33% (27).
TAVR outcomes have been reported in several patient
ubsets. In the Italian CoreValve registry, subclavian and TF
AVR had similar procedural success, composite safety,
nd 2-year survival (28). The median survival was 2.5 to 2.7
ears for patients with Society of Thoracic Surgeons mor-
ality risk 10% (29). Lower surgical risk patients have
etter TAVR outcomes than higher risk patients (30).
railty was an independent predictor of 1-year mortality
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p 0.0007), but not complications (31). Female gender was
ssociated with better 30-day and 1-year outcome (32,33).
ompared to TAVR in patients with left ventricular ejec-
ion fraction (LVEF) 35%, those with LVEF 35% had
igher 30-day mortality (10% vs. 3%, p 0.01), more PAR,
nd lower 1-year survival (69% vs. 87%, p  0.0001) (34).
ompared to TAVR in high-gradient AS, LF-LG AS
atients have more postoperative low output syndrome and
igher 30-day and 1-year mortality (12.8% vs. 7.4%, p 
.001; 36.9% vs. 18.1%, p 0.0001), but similar procedural
uccess, major complications, and functional improvement
35). TAVR patients with moderate or severe mitral regur-
itation (MR) had higher 30-day mortality, but similar
ortality at 1 year; MR improved in 55% of patients (36).
atients with severe AS and coronary artery disease (CAD)
re candidates for TAVR, as percutaneous coronary inter-
ention (PCI) can be performed without increased risk (37).
A recent review describes valve-in-valve (ViV) treatment
or bioprosthetic valve failure (38,39). The Global ViV
egistry reported ES and MCV ViV procedural success in
3%, 30-day mortality in 8.4%, and 1-year survival in 85.8%
40). MCV ViV was performed in 27 patients with failing
ioprosthetic aortic valves, with 30-day mortality of 7.4%
41). ViV therapy is also feasible for failed bioprosthetic
itral valves, using a TA approach (42). In PARTNER
ohort A, health-related quality of life (HRQOL) improved
ore rapidly after TF TAVR but was similar to AVR at 1
ear (43). Male gender and operator experience were inde-
endent predictors of HRQOL improvement (44). For
noperable AS, TAVR cost per quality-adjusted life-year
as comparable to other cardiovascular procedures (45).
AR after TAVR is classified as PAR, transvalvular AR
TAR), or both; PAR is an important predictor of adverse
utcome after TAVR. Various methods have been proposed
o reduce the incidence and severity of PAR after TAVR,
nd quantitate the degree of PAR during TAVR. Cross-
ectional CT annular dimensions are better than 2-dimensional
chocardiography to guide valve sizing and reduce PAR
46). CT-derived annulus area and valve undersizing were
ost predictive of PAR, whereas valve overexpansion re-
ulted in less PAR (47). The AR index [(diastolic blood
ressure – LV end-diastolic pressure systolic blood pressure] 
00) after device implantation has an inverse relationship
ith PAR severity; AR index 25 had significantly higher
-year mortality than AR index 25 (48,49).
Some centers have adopted a zero-tolerance policy for
nything more than mild PAR (50,51). Redilation in 28%
f ES TAVR patients resulted in reduction in 1 grade of
AR in 71%, and final PAR grade 2 in 54% (51).
edilation is less effective in patients with heavy valve
alcification, and marked overdistension can lead to aortic
njury, leaflet injury, and stroke (51). In contrast to PAR,
AR may be due to the guidewire, valve malposition, or
rosthetic leaflet dysfunction. While TAR due to the
uidewire usually resolves after guidewire removal, other wauses of TAR require definitive treatment. While trans-
atheter ViV implantation is safe and decreases TAR, it may
esult in higher residual transaortic valve gradients (50,52).
TAVR is associated with a higher risk of stroke than
VR. Transcranial Doppler identified intracranial emboli-
ation in all TAVR patients; no differences were seen
etween TA and TF ES. The highest intracranial signals
ere observed with TF MCV (53). Myocardial injury
biomarkers 5 times the upper normal limit) was observed
n 17% of MCV, and was an independent predictor of
0-day mortality (54). In the PARTNER trial, major
ascular complications at 30 days occurred in 15.3% due to
issection (62.5%), perforation (31.3%), and hematoma
22.9%) (55). Major vascular complications and baseline
enal disease were independent predictors of 1-year
ortality. Fortunately, most vascular complications can
e managed with stents and stent grafts, with a low risk
f restenosis (56).
Conduction disturbances are common after TAVR, and
ay impact late outcome. In 1 study of ES TAVR, 30% of
atients with normal baseline conduction developed new
eft bundle branch block (LBBB); LBBB persisted in 62.3%
t discharge and 42.7% at 6 to 12 months (57). Persistent
BBB was associated with longer baseline QRS duration
nd a more ventricular valve position. Persistent LBBB was
ssociated with symptomatic heart block and PPI, but not
-year mortality. In contrast, another study reported new
BBB after 51.1% of MCV and 12.0% of ES; new LBBB
as an independent predictor of 1-year mortality (58). In a
atched study of ES and AVR, baseline right BBB was a
trong predictor of PPI, and PPI was more frequent after
AVR (7.3% vs. 3.4%, p  0.014) (59). Compared to the
riginal MCV delivery system, the new Accutrak delivery
ystem had less PPI (14.3% vs. 35.1%, p  0.003) (60). PPI
fter MCV was associated with 2.37-fold higher risk of
-year mortality (61).
. Mitral valve disease. There were several excellent
eviews on echocardiography for percutaneous mitral valve
nterventions (62), quantitative assessment of MR (63–65),
nd surgical approaches to MR (66). In the EVEREST II
Endovascular Valve Edge-to-Edge Repair Study) study,
7% had pre-existing atrial fibrillation (AF) (67). Compared
o MitraClip (Abbott Vascular, Santa Clara, California)
atients without AF, patients with AF had similar proce-
ural success; freedom from death, mitral valve surgery, and
R 2; and safety at 12 months. In patients with
noperable MR, MitraClip reduced MR to 2 in 79%,
nd was associated with favorable LV remodeling at 6
onths (68). In a single-center study, 912 patients were
ollowed for up to 20 years after balloon mitral valvuloplasty
or mitral stenosis; 30% had sustained functional improve-
ent that was predicted by a scoring system relying on
mmediate residual transmitral gradient and area, age, gen-
er, valve calcification, and AF (69). Asymptomatic patients
ith moderate MS, favorable valve morphology, and good
1639JACC Vol. 61, No. 15, 2013 Dixon and Safian
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after balloon mitral valvuloplasty (70).
C. Paravalvular leak. Paravalvular regurgitation occurs in
5% to 17% of surgically implanted prosthetic heart valves,
leading to hemolysis, congestive heart failure, or both. A
recent review details the principles of paravalvular leak
repair (71).
D. Patent foramen ovale. Recent reviews describe the
anatomy of the foramen ovale (72), discuss strategies for
secondary stroke prevention (73), and detail the outcomes of
patent foramen ovale (PFO) closure (74). PFO closure
resulted in fewer recurrent neurological events compared to
medical therapy (11% vs. 21%; HR: 0.43; p 0.033) during
9-year follow-up (75). Three randomized trials of PFO
closure in patients with stroke/transient ischemic attack were
published or presented. A trial with the STARFlex device
(NMT Medical, Boston, Massachusetts) did not identify an
advantage for PFO closure compared to medical therapy
after 2 years (76). Two trials with the Amplatzer PFO
occluder (St. Jude Medical, St. Paul, Minnesota) reported
conflicting results, with 1 trial showing a reduction in stroke
risk in a per protocol analysis (77), and the other smaller
trial showing no significant benefit from closure (78).
E. Left atrial appendage occlusion. In the PROTECT
AF (Percutaneous Closure of the Left Atrial Appendage
versus Warfarin Therapy for Prevention of Stroke in Pa-
tients with Atrial Fibrillation) substudy, 32% had residual
flow in the left atrial appendage (LAA) 2 months after
Watchman (Boston Scientific, Plymouth, Minnesota) im-
plantation, which was not associated with increased throm-
boembolism (79). There may be a relationship between
LAA morphology and stroke: CT or magnetic resonance
imaging (MRI) of the LAA identified 4 distinct LAA
morphologic patterns, including cactus (30%), chicken wing
(48%), windsock (19%), and cauliflower (3%); the preva-
lence of prior stroke or transient ischemic attack was 12%,
4%, 10%, and 18%, respectively (80).
F. Hypertrophic cardiomyopathy. There are 2 general
reviews (81,82), a comprehensive review of pharmacological
treatment (83), and state-of-the-art review on the genetics
of hypertrophic cardiomyopathy (HCM) (84). Septal my-
ectomy resulted in marked attenuation of outflow gradient,
symptomatic improvement, and 1- and 5-year mortality of
0.8% and 3.3%, respectively (85). Residual LV outflow gradi-
ent was an independent predictor of late mortality after alcohol
septal ablation, but survival was similar to the general popula-
tion without HCM, and to age/gender matched HCM pa-
tients treated with surgical myectomy (86).
Elective PCI
A. Stable ischemic heart disease. In December 2012, a
new guideline for the diagnosis and management of patients
with stable ischemic heart disease (SIHD) was published
(updating the 2007 document) (87). Key elements of the
guideline include the role of testing for the initial diagnosisof SIHD, risk assessment, guideline-directed risk factor
modification, medical therapy recommendations, the role of
revascularization, and patient follow-up. Further discussion
is beyond the scope of this review, but all interventionalists
are encouraged to read this important document.
B. Fractional flow reserve. Fractional flow reserve (FFR)–
guided PCI plus best medical therapy was superior to a
strategy of medical therapy alone in patients with stable
CAD and a functionally significant stenosis (FFR 0.80)
(88). The difference in clinical events was primarily driven
by a reduced need for urgent revascularization in the PCI
group (HR with PCI: 0.13, p  0.001) (Fig. 1).
C. Multivessel revascularization. Results of an important
trial evaluating the optimal revascularization strategy in
1,900 diabetic patients with multivessel coronary disease
was reported (89). The primary endpoint (death, nonfatal
MI, or nonfatal stroke) was significantly lower in the
coronary artery bypass grafting (CABG) group (5-year rates
18.7% vs. 26.6%), driven by lower rates of both death and
MI. Stroke was more frequent in the CABG group. This
study will have an important impact on clinical practice.
D. Completeness of revascularization. There has been
controversy regarding the benefit of complete revasculariza-
tion (CR) in patients undergoing PCI or CABG. In a
detailed angiographic analysis of 2,954 acute coronary syn-
drome (ACS) patients, incomplete revascularization (ICR)
was observed in 37% (using a threshold of 50% diameter
stenosis in a vessel 2 mm diameter) (90). ICR was
strongly associated with higher 1-year rates of MI, un-
planned revascularization, and major adverse cardiac event
(MACE). Similarly, 10-year follow-up of the MASS II
(Second Medicine, Angioplasty, or Surgery Study) trial
reported that CR was associated with lower mortality
compared with ICR (91).
E. Appropriate use criteria (AUC). In 2012, a focused
update of the appropriate use criteria for coronary revascu-
larization was published (92). Indications for revasculariza-
tion were developed based on 5 key variables: 1) clinical
presentation; 2) severity of angina; 3) extent of ischemia on
noninvasive testing; 4) extent of medical therapy; and 5)
extent of anatomic disease. These criteria are intended to
assist clinicians with decision making regarding revascular-
ization, but should not be a substitute for thoughtful clinical
judgment. In 33,970 non-ACS patients in the New York
State Registry, 14% of PCI were rated inappropriate, many
of which had minimal or no anti-ischemic therapy or disease
not involving the proximal left anterior descending artery
(93). Adherence to the AUC for revascularization was
studied in 1,625 PCI patients with stable disease in Ontario
(94). Only 14% of revascularization procedures were
deemed inappropriate, however 30% of patients with ap-
propriate indications did not receive revascularization. Un-
deruse of revascularization in this group was associated with
an increased risk of adverse outcomes at 3 years.
F. Outcomes. An analysis of 426,996 patients65 years of
age revealed a higher periprocedural risk in women but
1640 Dixon and Safian JACC Vol. 61, No. 15, 2013
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comes was examined in 42,154 patients age 85 years of
age (96). A decline in drug-eluting stent (DES) use was
noted in all age groups, especially in these older patients.
Using data from 518,195 patients in the CathPCI Registry,
Weintraub et al. developed a model for predicting survival
up to 3 years after PCI in patients age 65 years (97).
G. Public reporting There has been debate about the
impact of public reporting on PCI outcomes. Utilization
and outcomes of PCI was compared in Medicare patients
with acute myocardial infarction (AMI) in states with and
without public reporting (98). Use of PCI, especially in
ST-segment elevation myocardial infarction (STEMI) and
cardiogenic shock, was lower in states with public reporting
however there was no difference in overall AMI mortality.
H. No on-site surgery. As the safety of contemporary PCI
has continued to improve, the need for on-site surgical
backup has been questioned. To address this issue, 18,867
patients were randomized to undergo PCI at a hospital
without on-site surgery or with on-site surgery (99). Pa-
tients with STEMI, EF 20% and left main PCI were
excluded. The mortality rate at 6 weeks (0.9% with on-site
surgery; 1.0% without on-site surgery), and incidence of
MACE at 9 months (12.1% vs. 11.2%) was similar in both
groups.
I. Bleeding. Temporal trends in post PCI bleeding were
assessed in 1 million PCI patients from 2005 to 2009
(100). An approximate 20% reduction in post-PCI bleeding
was observed during the study period, largely due to changes
in antithrombotic strategy (bivalirudin use increased from
Figure 1 Fractional Flow Reserve–Guided PCI Versus Medical T
Kaplan-Meier curve for the cumulative incidence of the primary endpoint of death,
assigned to percutaneous coronary intervention (PCI) and the best available medic
therapy alone, and the group that did not undergo randomization and was enrolled
permission from De Bruyne B et al. (88).17% to 30%; glycoprotein IIb/IIa use declined from 41% to28%). A recent consensus report from the Bleeding Aca-
demic Research Consortium (BARC) proposed a standard-
ized bleeding definition for post PCI bleeding. The validity
of this definition was tested in 12,459 patients undergoing
PCI and demonstrated a close association between bleeding
events according to BARC and 1-year mortality after PCI
(101).
J. Radial. Several trials compared outcomes between radial
and femoral access. In 7,021 patients, radial access was
associated with a reduction in clinical events (including
mortality) in patients with STEMI, but no difference was
seen in patients with non–ST-segment elevation ACS
(102). Two other randomized trials in STEMI reported
better clinical outcomes in patients treated via the radial
approach (103,104). In aggregate, these studies suggest that
the radial approach should be the preferred strategy in
primary PCI.
K. Left main. Several publications addressed PCI for
unprotected left main coronary artery (ULMCA) disease.
From 2004 to 2008, 5% of patients with ULMCA in the
National Cardiovascular Data Registry (NCDR) received
PCI; this was generally reserved for patients at high risk for
CABG (105). Although the SYNTAX score is an impor-
tant tool to help define the optimal revascularization strat-
egy in patients with ULMCA or 3-vessel disease, this does
not include clinical factors that impact prognosis. The Global
Risk classification, a new system that incorporates both the
SYNTAX score and EuroSCORE, appears to enhance risk
stratification and clinical decision making (106).
Two studies compared outcomes with DES for ULMCA
py in Stable Coronary Disease
rdial infarction, or urgent revascularization in the group that was randomly
rapy, the group that was randomly assigned to the best available medical
egistry (88). HR  hazard ratio; OMT  optimal medical therapy. Reprinted withhera
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year compared with first-generation paclitaxel-eluting stent
(PES) (107). In a 650-patient randomized trial of
zotarolimus-eluting stent (ZES) versus EES, similar angio-
graphic and clinical outcomes were observed at 8 and 12
months, respectively (108).
L. Chronic total occlusion. With the introduction of new
devices and techniques, there has been a resurgence of
interest in chronic total occlusion (CTO) intervention. In
150 CTO, technical success was achieved in 77% cases with
a novel crossing catheter and re-entry system (BridgePoint
Medical System, Plymouth, Minnesota) (109). Several ex-
cellent reviews described contemporary approaches to CTO
intervention including retrograde recanalization and subin-
timal dissection/re-entry strategies (110–112). In 3 experi-
enced centers, technical success was achieved in 81.4% of
462 retrograde CTO interventions (113). In a report from
the Canadian Multicenter Chronic Total Occlusions Reg-
istry, CTO was identified in 18% of patients with 50%
diameter stenosis in 1 coronary artery, however CTO inter-
vention was attempted in 10% lesions (114). A 208-patient
andomized trial comparing 2 DES in CTO reported the EES
as noninferior to sirolimus-eluting stents (SES) for angio-
raphic late loss at 9 months (115).
. High-risk PCI. In high-risk patients who are deemed
o require hemodynamic support during PCI, the optimal
upport device has not been defined. The PROTECT II
rial randomized 452 patients with ULMCA or 3-vessel
isease and severely depressed ventricular function to PCI
ith intra-aortic balloon pump (IABP) or the Impella 2.5
Abiomed, Danvers, Massachusetts) (116). The trial was
iscontinued early based on results of an interim analysis.
he Impella 2.5 provided superior hemodynamic support,
ut the primary endpoint (30-day adverse events) was not
ifferent between groups. At 90 days there was a trend
oward improved outcomes in the Impella arm.
. Drug-eluting balloon. A paclitaxel drug-eluting bal-
oon (DEB) was studied in de novo lesions in small vessels
2.8 mm) in 182 patients (117). At 6 months, angio-
raphic in-stent late loss was significantly less with DEB 
are-metal stents (BMS) compared with a PES. In a
,095-patient registry, use of the paclitaxel-DEB was asso-
iated with a low rate of target lesion revascularization
TLR) (5.2%) at 9 months (73% had restenosis) (118).
. Optical coherence tomography. A consensus docu-
ent provided standards for acquisition, measurement and
eporting of optical coherence tomography (OCT) studies
119). The article includes helpful tips on imaging tech-
iques, lesion assessment, and imaging artifacts. In another
eport, OCT was compared with FFR to determine the
ptimal threshold for hemodynamically significant stenosis.
CT had only a moderate diagnostic efficiency to detect a
ignificant stenosis (FFR 0.80) (area under the curve:
.74) with an optimal cutoff of 1.95 mm2 (120).
P. Contrast induced nephropathy. Several strategies were
tested to prevent contrast induced nephropathy (CIN). In 1report, LV end-diastolic pressure guided hydration (accord-
ing to a sliding scale) resulted in a 59% relative reduction in
CIN (121). The median hydration volume in the LV
end-diastolic pressure guided arm was 1711 ml compared
with 807 ml in the control arm. These data reaffirm the
importance of adequate hydration to prevent CIN. In
another study, furosemide-forced diuresis and intravenous
saline infusion matched with urine output (RenalGuard
System, PLC Medical Systems, Franklin, Massachusetts) was
associated with a lower rate of CIN compared with standard
hydration (122). In a novel approach, remote ischemic precon-
ditioning using 4 cycles of inflation-deflation of a blood
pressure cuff prior to contrast administration reduced the risk
of CIN in a small randomized trial (123).
Drug-Eluting Stents
A. BMS versus DES. An analysis of 76 randomized trials
comparing DES and BMS, with 117,762 patient years of
follow-up, reported that DES are highly efficacious at reducing
TVR without an increase in any safety outcomes including
stent thrombosis (ST) (124). The EES appeared to be the
safest stent. An 800-patient randomized trial of BMS versus
EES in octogenarians reported lower rates of TVR and MI
with EES and similar rates of major bleeding (125).
B. ST. Several studies evaluated the risk of late ST with
DES and BMS. In a network meta-analysis of 49 trials
including 50,844 patients, the cobalt-chromium EES had a
lower rate of definite ST at 1 year compared with other
DES (126) (Fig. 2). More importantly, the EES had a
significantly lower rate of definite ST at 2 years than BMS
(odds ratio: 0.35). In an observational study of 12,339
patients, the EES was also found to have a lower risk of very
late ST at 4 years compared with first-generation DES
(60% risk reduction) (127). A report from the Swedish
Coronary Angiography and Angioplasty Registry also sug-
gested lower rates of ST with second versus first-generation
DES (43% lower risk) (128). An 8,791-patient randomized
trial comparing 2 first-generation DES (Endeavor ZES and
Cypher SES) found no difference in the rate of definite/
probable ST at 3 years (129).
C. Second-generation DES. In patients with long lesions
(25 mm), the R-ZES (Resolute, Medtronic, Minneapolis,
Minnesota) was noninferior to SES for angiographic late
loss at 9 months (130). Two randomized trials comparing
EES with SES reported similar clinical outcomes at 1 year
(131,132). Two randomized trials compared the second-
generation R-ZES and Xience EES in relatively unre-
stricted patient populations and reported similar clinical
outcomes at 1 and 3 years (133,134).
D. Biodegradable polymers. DES with biodegradable
polymers have a lower risk of ST. Two randomized trials
compared 1-year clinical outcomes with the Nobori
abluminal biodegradable polymer biolimus-eluting stent
(BES) with a durable polymer DES. The BES was
noninferior to the EES (135), but in the other study
1642 Dixon and Safian JACC Vol. 61, No. 15, 2013
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An OCT study reported no difference in the rate of stent
malapposition with EES or BES at 6 to 8 months (137).
Similar 1-year clinical outcomes were also reported in a
trial comparing a SES with durable polymer and SES
with biodegradable polymer (138). A pooled analysis of 3
randomized trials demonstrated a lower rate of ST and
target lesion revascularization at 4 years with a biode-
gradable polymer DES compared with durable polymer
SES (139).
E. New DES. A small randomized trial evaluated a
thin-strut platinum-chromium stent that delivers everoli-
mus from an ultrathin bioabsorbable polymer applied
to the abluminal surface (140). Angiographic late loss
at 6 months was similar to an EES. A polymer-free
amphilimus-eluting stent (Cre8, CIS, Salugia, Italy) had
a lower in-stent late loss at 6 months than a permanent
polymer PES (141).
F. DES restenosis. The optimal treatment strategy for
Figure 2 Stent Thrombosis With DES and BMS
Pooled odds ratios and 95% confidence intervals determined by network meta-ana
BMS  bare-metal stent(s); CoCr-EES  cobalt-chromium everolimus-eluting stent
mus-eluting stent(s); PES  paclitaxel-eluting stent(s); PtCr-EES  platinum-chrom
SES  sirolimus-eluting stent(s). Reprinted with permission from Palmerini T et alDES restenosis has not been well defined. In a randomizedtrial, SES and EES achieved similar angiographic outcomes
at 9 months for diffuse restenosis (10 mm), but in focal
restenosis SES implantation was more effective than cutting
balloon alone (142). Use of a paclitaxel-eluting balloon was
superior to PTCA alone (143), and noninferior to PES
implantation (144).
G. Biodegradable scaffold. A paclitaxel-eluting bioab-
sorbable magnesium scaffold performed well with 12-month
late lumen loss of 0.52  0.39 mm and restoration of
acetylcholine-induced vasomotor function (145). At 10
years the fully biodegradable Igaki-Tamai stent was safe
with intravascular ultrasound studies showing complete
reabsorption of most struts within 3 years (146).
Primary PCI
A. STEMI guideline. The new American College of
Cardiology Foundation/American Heart Association
(ACCF/AHA) guideline for STEMI was published in
or 1-year (A), 2-year (B), early (C), and late (D) definite stent thrombosis.
S  drug-eluting stent(s); PC-ZES  phosphorylcholine polymer-based zotaroli-
erolimus-eluting stent(s); Re-ZES  resolute zotarolimus-eluting stent(s);
.lysis f
(s); DE
ium ev
. (126)December 2012 (147). The document provides a compre-
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on advances in reperfusion, organization of regional systems
of care, transfer algorithms, antithrombotic and medical
therapies, and secondary prevention strategies.
B. STEMI network. There is a growing body of evidence
to support the development of regional systems of care to
facilitate direct transfer of STEMI patients to primary PCI
centers. In a study of 1,389 STEMI patients in Ottawa,
patients who were transported directly to the PCI center
had significantly lower mortality at 180 days compared to
patients who were initially transported to a non-PCI center
(5.0% vs. 11.5%, p  0.0001) (148).
C. DES. In 907 patients use of SES was associated with
improved 1-year MACE compared with BMS (16.5% vs.
25.8%), primarily driven by a lower rate of TVR (149).
There was no difference in ST at 1 year. A meta-analysis of
15 randomized trials comparing first-generation DES and
BMS also reported an early benefit of DES, but increased
risk of ST after 1 year (150). Several trials investigated use
of second-generation DES in primary PCI. In 1 study, there
was no significant difference in 1-year MACE (death, MI,
any revascularization) between the EES and BMS, although
rates of TLR, TVR, and ST were lower with EES (151).
Another study reported noninferiority of EES compared
with SES in 625 AMI patients (152). A BES with a
biodegradable polymer resulted in lower MACE at 1 year
compared with BMS (153).
Dangas et al. studied clinical outcomes following defi-
nite/probable ST in 3,602 AMI patients during 3-year
follow-up (154). More than one-third of ST cases occurred
during the index hospitalization. This was associated with a
higher rate of mortality and MI, compared to ST occurring
out-of-the hospital.
D. New stents. Promising results were reported with use of
the MGuard stent (InspireMD, Tel Aviv, Israel), which is
novel thin-strut stent with a polyethylene terephthalate
micronet mesh covering designed to trap debris and prevent
distal embolization. In a 433-patient randomized trial, the
MGuard stent was associated with improved ST-segment
resolution and Thrombolysis In Myocardial Infarction flow
grade 3 compared with noncovered stents (155). A self-
expanding stent (STENTYS, Paris, France) resulted in less
stent strut malapposition at 3 days than a balloon expand-
able stent (156).
E. DEB. There has been interest in using a paclitaxel-
eluting balloon prior to BMS as an alternative strategy to
DES implantation in primary PCI. In a randomized trial of
150 patients, angiographic late loss at 6 months was similar
between BMS versus DEB plus BMS; both were inferior to
DES, and use of the DEB before BMS was also associated
with a higher rate of uncovered and malapposed struts (157).
F. Thrombectomy. In prior studies, there have been con-
icting results regarding the benefit of adjunctive throm-
ectomy in primary PCI. A total of 452 STEMI patients
ere randomized to undergo PCI with or without aspiration
hrombectomy and/or intracoronary abciximab (158). In-farct size by cardiac MRI, was not significantly different in
patients treated with thrombectomy compared with no
thrombectomy; however, infarct size was reduced in patients
who received intracoronary abciximab compared with no
abciximab (15.1% vs. 17.0%, p  0.03). In a trial of 2,065
patients, intracoronary abciximab did not improve clinical
outcomes compared with intravenous abciximab (159). An-
other trial reported that thrombectomy improved ST-
segment resolution but did not impact infarct size at 3
months (160).
G. Adjunctive therapies. Several studies evaluated novel
approaches to enhance myocardial salvage in primary PCI.
In 50 patients, post-conditioning was associated with a
smaller infarct size on cardiac MR and lower peak creatine
kinase (161). In contrast, a larger study of 700 patients
reported no difference in ST-segment resolution (the pri-
mary endpoint), or clinical outcomes at 1 month (162).
Exenatide, a glucagon-like peptide was studied in 172
STEMI patients and was associated with greater myocardial
salvage index at 3 months compared with placebo (163).
H. Shock. Mechanical circulatory support has been con-
sidered an integral part of the management of patients with
cardiogenic shock (CS). The IABP-SHOCK II (Intraaortic
Balloon Pump in Cardiogenic Shock) trial randomized 600
patients with CS complicating AMI to IABP or no IABP
(95.8% underwent PCI) (164). There was no difference in
the primary endpoint of 30-day mortality (IABP 39.7% vs.
control 41.3%), or any secondary endpoints. While these
data call into question the routine use of IABP support in
CS, critically ill patients who do not stabilize with pharma-
cologic support and early revascularization, may require
circulatory support with other novel devices.
I. Cell therapy. An exciting development was reported in
the field of cellular repair using cardiosphere-derived cells
(CDCs) as an alternative to autologous bone marrow cells.
CDCs were cultured from endomyocardial biopsy speci-
mens and administered via intracoronary injection 2 to 4
weeks after AMI (165). At 6 months, patients treated with
CDCs had reduced scar mass and an increase in viable heart
mass compared with controls. In another report, intracoro-
nary adipose tissue-derived regenerative cells (ADRCs)
appeared safe and feasible in 14 patients with anterior AMI
(166). An ongoing multicenter trial will evaluate the efficacy
of this approach. The TIME randomized trial studied the
optimal timing for intracoronary autologous bone marrow
cells after AMI (day 3 or day 7) (167). At 6 months, there
was no benefit of cell delivery on LV function or infarct
volume in either group.
Unstable Angina/NSTEMI
A focused update of the ACCF/AHA guidelines for man-
agement of patients with unstable angina (UA) and non–
ST-segment elevation myocardial infarction (NSTEMI)
was published in 2012 (168). Key areas of change include:
1) use of ticagrelor in patients with definite UA/NSTEMI
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planned (Class 1 recommendation); 2) duration of dual
antiplatelet therapy (DAPT) for UA/NSTEMI patients
managed with a conservative strategy modified to “up to 12
months”; 3) withdrawal of ticagrelor for at least 5 days in
patients in whom CABG is planned; 4) targeting a lower INR
(e.g., 2.0 to 2.5) in patients with UA/NSTEMI managed with
aspirin and a P2Y12 inhibitor who also have an indication for
anticoagulation (new recommendation).
A meta-analysis of 9 randomized trials (n  9,904)
evaluated the effect of invasive versus conservative manage-
ment in diabetic patients (169). A routine invasive strategy
significantly reduced the 1-year incidence of nonfatal MI
and rehospitalization in diabetic patients, but there was no
difference in the risk of death.
Pharmacotherapy
A. Duration of DAPT. Several studies addressed the
optimal duration of DAPT after DES implantation. In
1,443 patients there was no difference in target vessel failure
(death, MI, TVR) between 6 and 12 months DAPT;
however, this study was underpowered for death or MI
(170). In 2,117 patients, a strategy of Endeavor DES 3
months DAPT was found to the noninferior to 12-month
DAPT (171). Extended use DAPT was studied in 2,013
patients (75% DES) (172); 24-month DAPT did not
reduce the risk of death/MI/stroke compared with 6-month
DAPT, and was associated with a higher risk of bleeding
and transfusion. The risk of early DAPT discontinuation
was studied in 1,622 patients after DES implantation;
10.6% patients interrupted at least 1 antiplatelet within the
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Figure 3 Platelet Function Monitoring in PCI
Proportion of patients with primary outcome events, at 1 year of follow-up, the prim
transient ischemic attack, urgent coronary revascularization, and stent thrombosis
the conventional-treatment group. HR  hazard ratio. Reprinted with permission frfirst year (median 7 days) but this did not appear to be
associated with a significant increase rate of MACE (173).
B. Platelet function testing. Although hyporesponsive-
ness to antiplatelet therapy has been associated with adverse
clinical outcomes after stenting, there has been controversy
about the role of platelet function (PF) monitoring during
PCI. In a large 11,000-patient registry, on-treatment hypo-
responsiveness to clopidogrel was associated with higher
1-year ST and MI, lower major bleeding, but no difference
in mortality (174). Use of PF monitoring to adjust anti-
platelet therapy during and after stenting was studied in
2,440 patients (175). In the monitoring group, antiplatelet
therapy was adjusted according to results of the VerifyNow
P2Y12 (Accumetrics) and aspirin point-of-care assays.
High platelet reactivity with thienopyridine (235 platelet
reaction units) was observed in 34.5% patients in the cath
lab and 15.6% patients at 2 weeks. It should be noted that
only 12% patients in the monitoring arm received prasugrel.
At 1 year, there was no difference in the composite endpoint
(death, MI, ST, stroke, or urgent revascularization) between
groups (Fig. 3). Another study suggested that PF monitor-
ing might be necessary in patients treated with bivalirudin
compared with unfractionated heparin plus abciximab
(176). In a substudy of the TRILOGY ACS trial, prasugrel
resulted in lower platelet reactivity than clopidogrel among
ACS patients managed without revascularization; however,
there was no relationship between platelet reactivity and
ischemic outcomes (177).
C. Genotype testing. CYP2C19 polymorphisms have
been shown to impact the antiplatelet effect of clopidogrel
and clinical outcomes. A bedside point-of-care device was
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therapy according to CYP2C19*2 carrier status (carriers
received prasugrel, noncarriers received clopidogrel) leading
to a marked reduction in the proportion of CYP2C19*2
carriers with high on-treatment platelet reactivity (0% on
prasugrel vs. 30.4% on clopidogrel, p  0.009) (178).
D. Prasugrel. Use of prasugrel to correct high on-treatment
latelet reactivity with clopidogrel was studied in 423 stable
atients (179). At 3 months, 94.1% of patients on prasugrel
ad a PRU 208 compared with only 29.6% of clopidogrel
atients. Prasugrel dosing was studied in low-body weight
atients (60 kg); a 5mg dose resulted in similar platelet
nhibition to prasugrel 10 mg in patients 60 kg (180).
E. Ticagrelor. In 44 ACS patients with high on-treatment
platelet reactivity, ticagrelor produced higher platelet inhi-
bition at 15 days compared with prasugrel (181).
F. Cangrelor. Cangrelor, an intravenous, reversible P2Y12
platelet inhibitor, was evaluated as a bridging strategy in
patients with ACS or a coronary stent awaiting CABG, and
resulted in consistently lower levels of platelet reactivity
prior to surgery, without an increase in CABG-related
bleeding (182).
G. Elinogrel. Elinogrel is the only competitive and revers-
ible P2Y12 inhibitor with both oral and intravenous formu-
lations. In a randomized, dose-ranging phase 2b trial,
elinogrel was found to have acceptable safety and tolerability
compared with clopidogrel in 652 patients undergoing
non-urgent PCI (183).
H. Cilostazol. Cilostazol is a selective phosphodiesterase-3
inhibitor with antiplatelet and antiproliferative properties.
Triple antiplatelet therapy (aspirin, clopidogrel, and cilosta-
zol) was compared with aspirin  clopidogrel 150 mg daily
n 3,755 PCI patients (184). At 1 month, the rate of clinical
vents was noninferior with triple therapy.
. Vorapaxar. Platelet activation can also occur via the
rotease-activated receptor-1 on the platelet surface. Vora-
axar was evaluated in 12,944 ACS patients (58% under-
ent PCI) but did not reduce the composite endpoint
cardiovascular death, MI, stroke, hospitalization for is-
hemia, or urgent revascularization) and was associated with
ignificantly higher risk of bleeding including intracranial
emorrhage (185).
. Statins. Statin pre-treatment has been shown to reduce
eriprocedural myocardial injury during elective PCI, but
he efficacy of different statins has been unclear. In a
andomized study, high-dose atorvastatin 80 mg or rosuv-
statin 40 mg administered within 24 h of PCI in patients
lready on statin therapy resulted in similar reductions in
rocedural events (186).
. Rivaroxaban. In 7,817 STEMI patients (71% had PCI;
7% on thienopyridine) rivaroxaban (either 2.5 mg or 5 mg)
educed the risk of recurrent cardiovascular events, but
ncreased the risk of major bleeding (187).
. Concomitant anticoagulation. The optimal therapeu-
ic regimen in patients requiring concomitant antithrom-
otic and antiplatelet therapy is unclear. Bleeding risk in (atrial fibrillation patients admitted with MI or for PCI was
studied in 11,480 subjects in Denmark (188). Triple therapy
(warfarin, aspirin, clopidogrel) was associated with a high
early and sustained risk of bleeding compared to a vitamin K
antagonist plus single antiplatelet agent (1-year HR: 1.41).
There was no difference in the risk of thromboembolic
events between regimens. A randomized trial comparing
triple therapy versus warfarin clopidogrel in DES patients
demonstrated markedly higher bleeding events with triple
therapy and lower risk of stent thrombosis in the double
therapy arm (189). These data suggest that triple therapy
should be avoided and only be prescribed after careful
assessment of bleeding risk.
Vascular Disease
A. Peripheral arterial disease. There are several reviews on
medical therapy (190), surgical revascularization (191), en-
dovascular therapies (192), and appropriate use criteria for
vascular ultrasound and physiological testing (193). In a
randomized trial of aortoiliac disease, supervised exercise
resulted in greater improvement in walking time than
medical therapy or stenting, but quality-of-life improved
most with stenting (194). In the COBRA (Cryoplasty or
Conventional Balloon Post-Dilation of Nitinol Stents for
Revascularization of Peripheral Arterial Segments) trial,
angiographic restenosis at 12 months was significantly lower
after cryoplasty (29.3% vs. 55.8%, p  0.01) (195). In the
Italian Registry of the paclitaxel drug-eluting balloon
(PDEB) for severe femoropopliteal disease, procedural suc-
cess was 100%, stenting was required in 12.3%, and TLR
was 7.6% at 1 year (196). A meta-analysis of PDEB versus
angioplasty for femoropopliteal disease reported lower TLR
(12.2% vs. 27.7%, p  0.00001) at 10.3 months (197). In
patients with femoropopliteal in-stent restenosis, patency at
12 months was 92.1% after PDEB (198). Classification of
femoropopliteal in-stent restenosis by length and occlusion
had significant impact on recurrent restenosis (199). In 1
randomized trial, SES had lower angiographic restenosis
(22.4% vs. 41.9%, p 0.019) and higher patency (75.0% vs.
7.1%, p  0.025) than angioplasty for infrapopliteal
isease (200). In another randomized trial, SES had less
LR (9.2% vs. 20%, p  0.06) and amputation (2.6% vs.
2.2%, p  0.03) compared to BMS (201).
Fibromuscular dysplasia (FMD) was reviewed (202) and
eported in a large American registry (203). Active inflam-
ation (high erythrocyte sedimentation rate, C-reactive
rotein, and fibrinogen) was associated with a 7.5-fold
reater risk of vascular complications after surgical and
ndovascular revascularization in patients with Takayasu
rteritis (204).
. Carotid disease. The comparative effectiveness of ca-
otid revascularization was reviewed (205). Two MRI stud-
es described plaque hemorrhage, lipid core, and other
omplex features in patients with carotid wall thickening
206) and minor stroke (207). The National Cardiovascular
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and Endarterectomy Registry developed a simplified
weighted score (based on impending major surgery, previous
stroke, age, symptomatic status, atrial fibrillation, absence of
prior carotid endarterectomy) to predict in-hospital stroke
and death after carotid stenting (208). In the randomized
PROFI (Prevention of Cerebral Embolization by Proximal
Balloon Occlusion Compared to Filter Protection) study,
diffusion-weighted MRI demonstrated less cerebral emboli
after proximal embolic protection device (EPD) compared
to distal EPD (209).
C. Aortic aneurysm. A review detailed the pathophysiol-
ogy, clinical evaluation, and treatment of acute aortic
syndromes (AAS) (210). A recent Medicare study reported
that compared to open repair, endovascular repair (EVAR)
of abdominal aortic aneurysm (AAA) was associated with
shorter hospital stay (3.6 days vs. 10.4 days, p 0.001), and
lower all-cause and AAA-related mortality at 1 year (211).
A recent meta-analysis showed that EVAR had lower
all-cause mortality at 30 days (relative risk: 0.35), lower
AAA-related mortality at intermediate follow-up (relative
risk: 0.46), similar AAA-related and all-cause mortality at
long-term follow-up, and more reintervention during
follow-up (relative risk: 1.48 to 2.54) (212). In the random-
ized OVER (Open versus Endovascular Repair) trial,
EVAR was associated with lower mortality at 30 days and 3
years, but not thereafter (213). In all AAA trials, the most
common cause of late mortality is cardiovascular disease, so
patients should receive medical treatment for CAD.
D. Venous thromboembolism. A clinical prediction rule
for risk stratification of recurrent venous thromboembolism
in cancer patients was developed (214). Although 1 study
reported that aspirin can reduce recurrent venous thromboem-
bolism after therapeutic anticoagulation (215), another did not
(216). Oral rivaroxaban was noninferior to enoxaparin plus
vitamin K antagonists for early and late management of acute
pulmonary embolism (217). Catheter-directed pulmonary em-
bolectomy was recently reviewed (218).
Systemic Hypertension
Contemporary epidemiological studies differ in their assess-
ment of hypertension awareness, management, and control.
One study reported no improvement from 2007 to 2010
compared to 1999 to 2007 (219), whereas others showed
significant improvement resulting from performance mea-
sures, automatic notifications to care providers, electronic
reminders, and systematic revisits (219–222). In some
systems, only 2% of hypertension patients developed resis-
tant hypertension (RH), which was strongly associated with
cardiovascular events (223). Readers are referred to several
reviews on RH (224), the role of the sympathetic nervous
system (225), and renal denervation (RDN) for RH (226).
RDN resulted in significant reduction in cardiac work,
diastolic dysfunction, and LV mass (227,228). A state-
transition model suggested that RDN is highly cost-effective (229). In a randomized trial of patients with AF
and refractory hypertension, pulmonary vein isolation plus
RDN was more effective than pulmonary vein isolation
alone in controlling blood pressure and preventing recurrent
AF (230).
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